JPMorgan lifts target for Natera stock to USD 460.00

Published on 10/16/2026 at 15:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 752.75 million in the second quarter. Natera stock costs EUR 361.65 on October 16, 2026, up 0.82 percent versus Xetra close.

Analyst target and earnings date

JPMorgan set a USD 460.00 target for Natera on October 14, 2026.
Natera revenue reached USD 752.75 million in the second quarter of 2026.
Natera stock costs EUR 361.65 at Lang & Schwarz on October 16, 2026 at 3:31 p.m. CEST, 0.82 percent above the Xetra close of October 15, 2026.
Natera is scheduled to report third-quarter results on November 5, 2026.

NTRA, US6323071042, Illustration mit AI erstellt.

JPMorgan raised its price target for Natera from USD 360.00 to USD 460.00 and kept an Overweight rating on October 14, 2026, according to MarketBeat. The target stands 13.67 percent above Natera's Nasdaq price of USD 404.70 on October 16, 2026. Natera stock was trading at EUR 361.65 at Lang & Schwarz on October 16, 2026 at 3:31 p.m. CEST, plus 0.82 percent versus the Xetra close of October 15, 2026 at EUR 358.70.

Revenue growth remains central

Natera's second-quarter revenue rose 37.70 percent year over year to USD 752.75 million, compared with consensus revenue of USD 661.24 million. The company still reported a loss of USD 0.47 per diluted share, although that result was better than the consensus loss of USD 0.49, according to MarketBeat. The revenue comparison gives the current target debate an operating metric beyond the share price.

Stock stays below its yearly high

Natera's Nasdaq price of USD 404.70 at 9:35 a.m. ET on October 16, 2026 was below its 52-week high of USD 437.41 and above its 52-week low of USD 172.82. The distance to the high was 7.48 percent. The company's market capitalization was USD 58.3 billion on the same date, while the Lang & Schwarz quote was EUR 361.65.

In the latest quarterly period, operating cash flow was USD 54.79 million and total assets were USD 2.66 billion at June 30, 2026. Natera develops molecular testing services for reproductive health, oncology and organ transplantation, including Panorama, Signatera and Prospera.

Valuation and reporting date

Natera's next scheduled reporting date is November 5, 2026, after the market close, with a 4:30 p.m. ET conference call, according to MarketBeat. The same calendar page lists a consensus revenue estimate of USD 707.67 million and a consensus loss of USD 0.2697 per share for the third quarter of 2026. Those estimates are below the second-quarter revenue figure but point to continued year-over-year growth expectations.

Comparison with peers

Natera: plus 0.82 percent, market capitalization USD 58.3 billion.

Myriad Genetics (Nasdaq, USD): minus 2.07 percent, P/E minus 3.60, market capitalization USD 407.5 million.

Illumina (Nasdaq, USD): plus 1.00 percent, P/E 50.75, market capitalization USD 40.9 billion.

Euro quote and trading position

The euro quote places Natera above its October 15 Xetra close while the Nasdaq price remains below the 52-week high. The current quote is an intraday indication rather than a closing price.

The further course of trading is shown by the continuously updated real-time quote of Natera stock.